About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Hong Kong, with R&D and management resources in the USA, China, Canada, UAE, Belgium, UK, and Taiwan sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico Medicine pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief.
Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8
For more information, please visit http://www.insilico.com
|
|
|
11-50 employees
View all Insilico Medicine, Inc employees
|
|
Biotechnology
|
|
1 Science Park East Avenue, Hong Kong Science Park, Pak Shek Kok, Unit 307A, Core Building 1, New Territories, HK
|
|
2014
|
|
Drug Discovery, Artificial Intelligence, Deep Learning, Longevity, Aging Research, Biomarker Development, Reinforcement Learning, Gans, Generative Adversarial Networks, Gans-Rl
|
Insilico Medicine, Inc Alternatives
Frequently Asked Questions about Insilico Medicine, Inc
Feng Ren is the CEO of Insilico Medicine. To contact Feng Ren email at [email protected].
The decision makers in Insilico Medicine are Andy Min Xie, Andy Xie, Daniil Polykovskiy, etc. Click to Find Insilico Medicine decision makers emails.
Insilico Medicine, Inc Staff Directory
Search Insilico Medicine, Inc Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
